Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05464511

Impact of Steerable Delivery Sheaths on Successful Closure of LA A With AMULET

The novel Amplatzer steerable delivery sheath (Abbott Vascular) is found to be safe and effective in performing LAAO procedure. However, the procedural outcomes have not been compared with the traditional non-steerable fixed curve sheath. In this study investigators aim to compare the outcome of patients undergoing left atrial appendage occlusion with the dual mechanism closure Amulet device using non-steerable fixed curve sheath versus a novel steerable sheath.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kansas City Heart Rhythm Institute, Overland Park, Kansas, United States

Loading trial locations.

About this study

Atrial fibrillation (AF) is the most common abnormal heart rhythm associated with substantial morbidity and mortality. It is one of the strongest risk factors of systemic thromboembolism (TE), with stroke being the most serious outcome. Prevention of stroke is the cornerstone of managing AF, which can be achieved either by oral anticoagulation (OAC) or Percutaneous left atrial appendage occlusion (LAAO) in patients who have a contraindication to OAC. Heterogeneity in cardiac chamber size, interatrial septum, LAA anatomy and orientation, operator experience and currently available fixed curve sheaths add to the complexity of the procedure. Alignment of LAAO device along the access of the left atrial appendage body is an important factor in improving closure rates. The devices which are currently approved by FDA for LAA closure in the U.S. are Amplatzer Amulet device (Abbott Medical) and Watchman and Watchman FLX devices (Boston Scientific). In a recent study, Amplatzer Amulet device was found to be noninferior in terms of safety and effectiveness, with superior LAA occlusion rates but higher device-related complications as compared to first generation watchman device. The LAAO device sheaths that are used currently have fixed shapes and angles that may not be optimal for some LAA anatomy, which can lead to excessive device manipulation, prolonged procedure time, and potentially suboptimal co-axiality during the process. This may lead to increase device related complications. The new Amplatzer steerable delivery sheath (Abbott Vascular) is designed to provide distal bidirectional steerability of the sheath for Amulet implantation. Such steerability may enable successful endovascular closure of greater proportion of LAA, allow precise position of the transseptal puncture, and potentially reduce procedural times and complications with complex cases.

Investigators hypothesize that the use of novel steerable sheath for LAAO closure is safer and more effective as compared to non-steerable fixed curve sheath

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with atrial fibrillation who meets the indication/criteria for left atrial appendage occlusion and undergoing implantation of Amplatzer™ Amulet™ Left Atrial Appendage Occluder device

Exclusion criteria

  • Patient been/being implanted with device other than Amplatzer™ Amulet™ Left Atrial Appendage Occluder
  • Pregnant or breastfeeding patients
  • Prisoners
  • Patients not willing to participate in the study

Treatment and study plan

Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.

Other

Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.

Primary outcomes

  1. Number of participants with Acute Closure of Left Atrial Appendage

    Time frame: 1 day

    Acute closure ( less than or equal to 3mm) of the left atrial appendage after Left Atrial Appedage Occlusion(LAAO) procedure

  2. Number of patients with Cardiac Perforation

    Time frame: 7 days

    Number of patients with cardiac perforation

  3. Need for Pericardiocentesis

    Time frame: 7 days

    Need for pericardiocentesis within 7 days of implantation

Secondary outcomes

  1. Number of devices

    Time frame: 1 day (procedure day)

    Number of devices changed prior to final implant during the procedure

  2. Number of device repositions

    Time frame: 1 day (procedure day)

    Number of device repositions performed during the procedure

  3. Closure Rates

    Time frame: 45 days

    45 day closure rates of left atrial appendage ( less than or equal to 3mm)

  4. Number of participants with Device related thrombus (DRT)

    Time frame: 45 days

    Number of participants with Device related thrombus (DRT)

  5. Number of participants with Transient ischemic attack (TIA) or cerebrovascular accident (CVA)

    Time frame: 6 months

    Number of participants with Transient ischemic attack (TIA) or cerebrovascular accident (CVA) within 6 months of the procedure

Study contacts

Contact information is provided by the study sponsor or research team.

Donita Atkins

CONTACT

[email protected]

816-651-1969

Sponsors and collaborators

Lead sponsor

Kansas City Heart Rhythm Research Foundation

Other

Collaborators

  • Kansas City Heart Rhythm Institute

Registry information

Official study title

Impact of Steerable Delivery Sheaths on Successful Closure of Left Atrial Appendage With AMULET Dual Mechanism Closure Device (STEER-CLOSE Study)

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 19, 2022
Registry last updated
Aug 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.